Efficient Neutralizing Activity of Cocktailed Recombinant Human Antibodies Against Hepatitis a Virus Infection in Vitro and in Vivo
Jingyuan Cao,Shufang Meng,Chuan Li,Yan Ji,Qingling Meng,Quanfu Zhang,Feng Liu,Jiandong Li,Shengli Bi,Dexin Li,Mifang Liang
DOI: https://doi.org/10.1002/jmv.21212
IF: 20.693
2008-01-01
Journal of Medical Virology
Abstract:Hepatitis A virus (HAV) is the major pathogen responsible for acute infectious hepatitis A, a disease that is prevalent worldwide. Although HAV immunization effectively prevents infection, primary immunizations must be administered at least 2 weeks prior to HAV exposure. In contrast, passive immunization with pooled human immunoglobulin (Ig) can provide immediate and rapid protection from HAV infection. Because the use of human sera‐derived Igs carries the risk of contamination, we sought to develop recombinant HAV‐neutralizing human antibodies. We prepared a combinatorial phage display library of recombinant human anti‐HAV antibodies from RNA extracted from the blood lymphocytes of a convalescent hepatitis A patient. Two recombinant human IgG antibodies, HAIgG16 and HAIgG78, were screened from the antibody library by their ability to bind with high affinity to purified, inactivated HAV virions. These antibodies recognized different epitopes of the HAV virion capsid, and competed with both patient sera and well‐characterized neutralizing mouse monoclonal antibodies. A cocktailed mixture of HAIgG16 and HAIgG78 at a 3:1 ratio was prepared to compare its combined biological activity with that conferred by each antibody individually. The cocktailed antibodies displayed a stronger neutralizing activity in vitro than that observed with either HAIgG16 and HAIgG78 alone. To determine the in vivo neutralizing abilities of these antibodies, rhesus monkeys were inoculated with cocktailed antibodies and challenged with HAV. Whereas control animals developed hepatitis A and seroconverted to the HAV antibody, animals receiving cocktailed antibodies were protected either from viral infection or from developing clinical hepatitis. These results demonstrate that recombinant human antibody preparations could be used to prevent or treat early‐stage HAV infection. J. Med. Virol. 80: 1171–1180, 2008. © 2008 Wiley‐Liss, Inc.